Non-pathogenic Trojan horse <i>Nissle1917</i> triggers mitophagy through PINK1/Parkin pathway to discourage colon cancer.

ABSTRACT: Bacteria-mediated antitumor therapy has gained widespread attention for its innate tumor-targeting capability and excellent immune activation properties. Nevertheless, the clinical approval of bacterial therapies remains elusive primarily due to the formidable challenge of balancing safety with enhancing in vivo efficacy. In this study, leveraging the probiotic Escherichia coli Nissle1917 (EcN) emerges as a promising approach for colon cancer therapy, offering a high level of safety attributed to its lack of virulence factors and its tumor-targeting potential owing to its obligate anaerobic nature. Specifically, we delineate the erythrocyte (RBC) membrane-camouflaged EcN, termed as Trojan horse EcN@RBC, which triggers apoptosis in tumor cells by mitigatin

SUBMITTER: Wang Y 

PROVIDER: S-EPMC11480251 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature